Cytek Biosciences Inc
CTKB5.100USD
+0.030+0.59%
Cierre 12/26, 16:00（ET）Cotizaciones retrasadas 15 min
652.11MCap. mercado
PérdidaP/E TTM
Más Datos de Cytek Biosciences Inc Compañía
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
Información de Cytek Biosciences Inc
Símbolo de cotizaciónCTKB
Nombre de la empresaCytek Biosciences Inc
Fecha de salida a bolsaJul 23, 2021
Director ejecutivoJiang (Wenbin)
Número de empleados648
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 23
Dirección47215 Lakeview Boulevard
CiudadFREMONT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94538
Teléfono18779229835
Sitio Webhttps://cytekbio.com
Símbolo de cotizaciónCTKB
Fecha de salida a bolsaJul 23, 2021
Director ejecutivoJiang (Wenbin)
Ejecutivos de Cytek Biosciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.07M
+0.26%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.36M
+0.79%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
115.64K
+16.63%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--
Mr. Michael Holder
Mr. Michael Holder
Independent Director
Independent Director
12.36K
+21.43%
Mr. William (Bill) Mccombe
Mr. William (Bill) Mccombe
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jack T. Ball, Jr.
Mr. Jack T. Ball, Jr.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.07M
+0.26%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.36M
+0.79%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
115.64K
+16.63%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
23.89M
52.40%
EMEA
12.31M
26.99%
APAC
7.87M
17.25%
Other
1.53M
3.36%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
11.89%
Topline Capital Management, LLC
5.43%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.75%
Otro
67.30%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
11.89%
Topline Capital Management, LLC
5.43%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.75%
Otro
67.30%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
28.05%
Investment Advisor/Hedge Fund
22.30%
Hedge Fund
9.95%
Individual Investor
9.31%
Research Firm
1.43%
Pension Fund
1.21%
Bank and Trust
0.17%
Family Office
0.12%
Venture Capital
0.06%
Otro
27.39%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
319
80.93M
70.83%
-2.20K
2025Q3
325
80.93M
70.98%
+589.69K
2025Q2
322
80.49M
71.67%
+1.88M
2025Q1
319
78.68M
72.45%
-13.77M
2024Q4
315
78.50M
69.87%
+2.46M
2024Q3
291
75.89M
70.06%
-1.14M
2024Q2
277
76.97M
68.86%
-4.44M
2024Q1
273
87.08M
76.11%
-12.82M
2023Q4
268
85.37M
77.21%
+1.48M
2023Q3
258
83.84M
73.24%
+597.32K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
15.38M
12.09%
-1.12M
-6.80%
Jun 30, 2025
Topline Capital Management, LLC
5.23M
4.11%
+3.76M
+255.68%
Jun 30, 2025
The Vanguard Group, Inc.
7.74M
6.08%
-1.86M
-19.35%
Jun 30, 2025
HHLR Advisors, Ltd.
6.66M
5.23%
--
--
Jun 30, 2025
Yan (Ming)
6.06M
4.76%
+15.29K
+0.25%
Aug 18, 2025
Jiang (Wenbin)
5.31M
4.18%
+52.68K
+1.00%
Aug 18, 2025
Brown Capital Management, LLC
7.11M
5.59%
-353.97K
-4.74%
Jun 30, 2025
State Street Investment Management (US)
4.17M
3.28%
-208.41K
-4.76%
Jun 30, 2025
Millennium Management LLC
924.77K
0.73%
+429.33K
+86.66%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.45M
2.72%
+601.00K
+21.06%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco S&P SmallCap Health Care ETF
0.26%
Royce Quant Small-Cap Quality Value ETF
0.22%
iShares S&P Small-Cap 600 Value ETF
0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.07%
State Street SPDR S&P 600 Small Cap Value ETF
0.06%
Avantis US Small Cap Equity ETF
0.05%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.05%
Principal U.S. Small-Cap ETF
0.05%
WisdomTree US SmallCap Fund
0.04%
Ver más
Invesco S&P SmallCap Health Care ETF
Proporción0.26%
Royce Quant Small-Cap Quality Value ETF
Proporción0.22%
iShares S&P Small-Cap 600 Value ETF
Proporción0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.07%
State Street SPDR S&P 600 Small Cap Value ETF
Proporción0.06%
Avantis US Small Cap Equity ETF
Proporción0.05%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
Proporción0.05%
Fidelity Enhanced Small Cap ETF
Proporción0.05%
Principal U.S. Small-Cap ETF
Proporción0.05%
WisdomTree US SmallCap Fund
Proporción0.04%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Cytek Biosciences Inc?
Los cinco principales accionistas de Cytek Biosciences Inc son:
BlackRock Institutional Trust Company, N.A. posee 15.38M acciones, lo que representa el 12.09% del total de acciones.
Topline Capital Management, LLC posee 5.23M acciones, lo que representa el 4.11% del total de acciones.
The Vanguard Group, Inc. posee 7.74M acciones, lo que representa el 6.08% del total de acciones.
HHLR Advisors, Ltd. posee 6.66M acciones, lo que representa el 5.23% del total de acciones.
Yan (Ming) posee 6.06M acciones, lo que representa el 4.76% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 15.38M acciones, lo que representa el 12.09% del total de acciones.
Topline Capital Management, LLC posee 5.23M acciones, lo que representa el 4.11% del total de acciones.
The Vanguard Group, Inc. posee 7.74M acciones, lo que representa el 6.08% del total de acciones.
HHLR Advisors, Ltd. posee 6.66M acciones, lo que representa el 5.23% del total de acciones.
Yan (Ming) posee 6.06M acciones, lo que representa el 4.76% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Cytek Biosciences Inc?
Los tres principales tipos de accionista de Cytek Biosciences Inc son:
BlackRock Institutional Trust Company, N.A.
Topline Capital Management, LLC
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Topline Capital Management, LLC
The Vanguard Group, Inc.
¿Cuántas instituciones poseen acciones de Cytek Biosciences Inc (CTKB)?
A fecha de 2025Q4, 319 instituciones poseen acciones de Cytek Biosciences Inc, con un valor de mercado combinado de aproximadamente 80.93M, lo que representa el 70.83% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -0.14%.
¿Cuál es la mayor fuente de ganancias de Cytek Biosciences Inc?
El FY2025Q2, el segmento empresarial Biotechnology, pharmaceutical, distributor and CRO generó la ganancia más alta para Cytek Biosciences Inc, ascendiendo a 23.85M y representando el 52.30% de la ganancia total.
